Bassetti M, Righi E, Rosso R, Mannelli S, Di Biagio A, Fasce R, Pallavicini F Bobbio, Marchetti F, Viscoli C
Infectious Diseases Department, S. Martino Hospital and University of Genoa, Genoa, Italy.
Int J Antimicrob Agents. 2006 Dec;28(6):582-5. doi: 10.1016/j.ijantimicag.2006.08.006. Epub 2006 Sep 18.
To investigate the efficacy and tolerability of treatment with a combination of levofloxacin and ceftazidime in Gram-negative hospital-acquired pneumonia (HAP) in the Intensive Care Unit (ICU), we performed a prospective, open-label, non-comparative, 1-year study in an Italian ICU. Patients received levofloxacin 500 mg twice a day intravenously plus ceftazidime 2 g three times a day intravenously for 7-14 days. Primary efficacy variables were clinical and microbiological responses at test-of-cure visit. Twenty-one patients were enrolled. Pseudomonas aeruginosa and Klebsiella pneumoniae were the most frequently identified pathogens. Clinical success was achieved in 17/21 clinically evaluable patients (81%) and in 12/15 microbiologically evaluable patients (80%). Regarding only the group with ventilator-associated pneumonia, cure was achieved in 10/14 clinically evaluable patients (71%) and in 11/14 microbiologically evaluable patients (79%). Therapy was well tolerated. We conclude that this combination regimen is safe and clinically and microbiologically efficacious in the treatment of Gram-negative HAP.
为了研究左氧氟沙星和头孢他啶联合治疗重症监护病房（ICU）革兰阴性医院获得性肺炎（HAP）的疗效和耐受性，我们在意大利一家ICU进行了一项前瞻性、开放标签、非对照的为期1年的研究。患者接受左氧氟沙星500mg静脉注射，每日2次，加头孢他啶2g静脉注射，每日3次，共7 - 14天。主要疗效变量是治愈检查访视时的临床和微生物学反应。共纳入21例患者。铜绿假单胞菌和肺炎克雷伯菌是最常见的病原体。在17/21例可进行临床评估的患者（81%）和12/15例可进行微生物学评估的患者（80%）中取得了临床成功。仅就呼吸机相关性肺炎组而言，在10/14例可进行临床评估的患者（71%）和11/14例可进行微生物学评估的患者（79%）中实现了治愈。治疗耐受性良好。我们得出结论，这种联合方案在治疗革兰阴性HAP方面是安全的，并且在临床和微生物学上均有效。
